Sigilon Therapeutics Total Current Liabilities

Sigilon Therapeutics (SGTX) currently reports a total current liabilities of $25M as of June 2023. That compares with $33M in the prior-year period — down 24.2% year over year. Use the charts on this page to explore Sigilon Therapeutics's total current liabilities history and peer comparisons.

Sigilon Therapeutics's total current liabilities decreased from $33M to $25M — a 24.2% year-over-year decrease (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sigilon Therapeutics reported $25M in total current liabilities as of June 2023. That compares with $33M in the prior-year period — down 24.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $25M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Sigilon Therapeutics, and consider following SGTX for alerts when major investors trade the stock.

Sigilon Therapeutics is classified in the Healthcare sector. On total current liabilities, it currently shows $25M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SGTX with unrelated industries.